DB17840InvestigationalProtein Based Therapies
AGA2115 is a humanized bispecific antibody neutralizing both sclerostin and Dickkopf-1. Developed by Angitia Biopharmaceuticals, AGA2115 is being investigated for the treatment of osteogenesis imperfect.
- Code names
- AGA2115
Resolves to
Compound
What you can answer from here — as of January 20, 2026
Which companies are running trials of AGA2115, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account